This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
If you're looking for a hidden gem in the biotech sector, you might want to check out Stoke Therapeutics (NASDAQ: STOK). This company is developing innovative therapies for rare genetic diseases that represent a high degree of unmet medical need.
And according to Wall Street analysts, the small-cap biotech has the potential to deliver a staggering 277% return over the next 12 months.
Image source: Getty Images.
Source Fool.com